Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
14 juin 2021 07h01 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Announces June 2021 Investor Conference Schedule
25 mai 2021 07h30 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today...
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
13 mai 2021 16h02 HE
|
Nkarta, Inc.
NKX019 IND received FDA clearance; NKX019 patient dosing expected to start in 2H 2021Protocol amendment to ongoing NKX101 clinical trial adds a second multi-dosing regimen and a shorter waiting period...
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
28 avr. 2021 08h02 HE
|
Nkarta, Inc.
NKX019 to be Nkarta’s second CAR NK pipeline program to enter clinical trial SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company...
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
25 mars 2021 16h03 HE
|
Nkarta, Inc.
Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor, in acute myeloid leukemia (AML) and myelodysplastic syndrome...
Nkarta Announces February and March 2021 Investor Conference Schedule
17 févr. 2021 16h03 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Reports Third Quarter 2020 Financial Results
12 nov. 2020 16h03 HE
|
Nkarta, Inc.
First patient dosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromesIND application for NKX019...
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
12 nov. 2020 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
09 nov. 2020 08h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Announces November & December 2020 Investor Conference Schedule
05 nov. 2020 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...